Optodrop-Co (Dorzolamide Hydrochloride, Timolol Maleate)

Dorzolamide Hydrochloride / Timolol Maleate, the active ingredient in Optodrop-Co, is a carbonic anhydrase inhibitor / beta blocker presented as an unknown strength/eye drops for ocular use. It lowers intraocular pressure in adults with open‑angle glaucoma or ocular hypertension, and is indicated for the management of elevated pressure to help prevent optic nerve damage and visual field loss.

GNH USA supplies Optodrop-Co as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with rigorous quality assurance and regulatory compliance across EU markets.

Optodrop-Co combines dorzolamide and timolol to lower intraocular pressure in glaucoma and ocular hypertension.

Open-angle glaucoma: reduces intraocular pressure to slow optic nerve damage. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Secondary glaucoma: provides additional pressure control when monotherapy is insufficient.

Optodrop-Co may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Eye irritation or burning: transient discomfort after instillation. - Blurred vision: temporary visual disturbance. - Dry eye sensation: mild dryness. - Taste alteration: bitter taste after drops. - Conjunctival hyperemia: mild redness. - Reduced tear production: occasional dryness.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Corneal edema: swelling of the cornea affecting vision. - Systemic bradycardia: slowed heart rate, especially in patients with cardiac disease. - Bronchospasm: airway constriction in asthmatic patients. - Acute angle‑closure glaucoma: paradoxical pressure rise. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before prescribing Optodrop-Co, clinicians should evaluate patient history and monitor for specific risks.

- Cardiovascular assessment: check for bradycardia, heart block, or heart failure. - Respiratory evaluation: avoid in patients with asthma or COPD due to bronchospasm risk. - Pregnancy and lactation: use only if benefit outweighs potential risk; data limited. - Concomitant beta‑blockers: monitor for additive systemic effects such as hypotension. - Contact lens wear: advise removal before instillation as lenses may retain drug. - Store at room temperature: keep in original container, protect from light and moisture.

Optodrop-Co can interact with systemic and ocular medications, altering efficacy or safety.

Major Interactions (Avoid): - Systemic beta‑blockers: may cause excessive bradycardia or hypotension. - Non‑selective beta‑blockers (e.g., propranolol): increase risk of bronchospasm. - Other ocular carbonic anhydrase inhibitors (e.g., acetazolamide): may lead to over‑reduction of intraocular pressure.

Moderate Interactions (Monitor Closely): - Topical sympathomimetics (e.g., phenylephrine): may diminish pressure‑lowering effect. - Systemic carbonic anhydrase inhibitors (e.g., oral acetazolamide): additive IOP reduction. - Anticholinergic eye drops: may affect pupil dynamics and drug absorption.